Compare LITE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LITE | IKT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.1B | 201.3M |
| IPO Year | N/A | 2020 |
| Metric | LITE | IKT |
|---|---|---|
| Price | $395.00 | $1.87 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 3 |
| Target Price | ★ $198.50 | $6.00 |
| AVG Volume (30 Days) | ★ 3.6M | 660.2K |
| Earning Date | 02-03-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $1,841,900,000.00 | N/A |
| Revenue This Year | $61.58 | N/A |
| Revenue Next Year | $31.87 | N/A |
| P/E Ratio | $255.13 | ★ N/A |
| Revenue Growth | ★ 33.62 | N/A |
| 52 Week Low | $45.65 | $1.33 |
| 52 Week High | $401.60 | $3.47 |
| Indicator | LITE | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.21 | 56.15 |
| Support Level | $339.02 | $1.56 |
| Resistance Level | $401.60 | $2.16 |
| Average True Range (ATR) | 24.33 | 0.19 |
| MACD | -2.15 | 0.02 |
| Stochastic Oscillator | 92.09 | 51.72 |
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.